Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
Citations Over TimeTop 10% of 2017 papers
Abstract
Although checkpoint inhibitor therapies have demonstrated significant efficacy in many malignancies, they have not been well studied in patients with a history of solid organ transplant. We describe two patients with recurrent, refractory, and progressive advanced fibrolamellar hepatocellular carcinoma (HCC) following orthotopic liver transplantation who received programmed cell death protein 1 (PD-1) inhibitor, nivolumab, on a patient access, off-label basis. Both rapidly developed irreversible acute liver rejection shortly after starting therapy, and ultimately died. While checkpoint inhibitors clearly have tremendous potential as a targeted therapy, they should be avoided or used with extreme caution in the context of an organ transplant.
Related Papers
- → Nivolumab-refractory patients with advanced non-small-cell lung cancer(2019)18 cited
- → Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma(2020)11 cited
- → Exam 2: Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria(2012)9 cited
- → Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma(2020)8 cited
- → Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?(2008)1 cited